This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (61)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Thrombolysis  • Neurology  • Stroke  • Cardiovascular System  • Arrhythmias  • Alert me on articles by topic  Social Bookmarking   What's this?

Andrew Evans, MRCP; Lalit Kalra, PhD, FRCP

Arch Intern Med. 2001;161:1443-1447.

Background  Randomized trials demonstrate a clear benefit of anticoagulation in patients with atrial fibrillation at risk of stroke, but the proportion of eligible patients who are treated with anticoagulants remains low. The reluctance to treat all eligible patients with anticoagulants may be due to studies in clinical practice showing variable risk-benefit, raising concerns about application to general medical practice.

Methods  A systematic review of published medical literature was performed to identify studies of patients with atrial fibrillation who were treated with warfarin in actual clinical practice. Data from these studies were compared with pooled data from randomized controlled trials.

Results  Three studies met the predefined criteria, each in a different health care setting, totaling 410 patients with 842 patient-years of follow-up. Patients in clinical practice were older and had more comorbid conditions compared with trial participants. However, the ischemic stroke rate was similar between clinical practice and randomized studies (1.8% [95% confidence interval {CI}, 0.9%-2.7%] vs 1.4% [95% CI, 0.9%-2.0%]). Intracranial hemorrhage (0.1% [95% CI, 0%-0.3%] vs 0.3% [95% CI, 0.06%-0.5%]) and major bleeding (1.1% [95% CI, 0.4%-1.8%] vs 1.3% [95% CI, 0.8%-1.8%]) rates were also similar. There was a higher rate of minor bleeding in clinical practice than in trials (12.0% [95% CI, 9.7%-14.3%] vs 7.9% [95% CI, 6.6%-9.2%]).

Conclusions  Patients who undergo anticoagulation for atrial fibrillation in actual clinical practice differ from those in randomized trials, but have similar rates of stroke and major bleeding. The risk of minor bleeding is higher and may require more intensive monitoring in practice.

From the Department of Diabetes, Endocrinology, and Internal Medicine, Guy's, King's and St Thomas' School of Medicine, King's College, London, England.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 2001;161(11):1463-1464.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Cost-Effectiveness of Genotype-Guided Warfarin Dosing for Patients With Atrial Fibrillation
Patrick et al.
Circ Cardiovasc Qual Outcomes 2009;2:429-436.
ABSTRACT | FULL TEXT  

Warfarin for the prevention of systemic embolism in patients with non-valvular atrial fibrillation: a meta-analysis
Andersen et al.
Heart 2008;94:1607-1613.
ABSTRACT | FULL TEXT  

Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Schulman et al.
Chest 2008;133:257S-298S.
ABSTRACT | FULL TEXT  

Antithrombotic Therapy in Atrial Fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Singer et al.
Chest 2008;133:546S-592S.
ABSTRACT | FULL TEXT  

A Cautionary Note on Data Sources for Evidence-Based Clinical Decisions: Warfarin and Stroke Prevention
Thomson et al.
Med Decis Making 2007;27:438-447.
ABSTRACT  

Antithrombotic treatment in atrial fibrillation
Kalra et al.
Heart 2007;93:39-44.
FULL TEXT  

Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation.
Hron et al.
JAMA 2006;296:397-402.
ABSTRACT | FULL TEXT  

Mixed comparison of stroke prevention treatments in individuals with nonrheumatic atrial fibrillation.
Cooper et al.
Arch Intern Med 2006;166:1269-1275.
ABSTRACT | FULL TEXT  

The Belgian Improvement Study on Oral Anticoagulation Therapy: a randomized clinical trial
Claes et al.
Eur Heart J 2005;26:2159-2165.
ABSTRACT | FULL TEXT  

Preference-Based Antithrombotic Therapy in Atrial Fibrillation: Implications for Clinical Decision Making
Man-Son-Hing et al.
Med Decis Making 2005;25:548-559.
ABSTRACT  

Perioperative Management of Patients on Oral Anticoagulants: A Decision Analysis
Dunn et al.
Med Decis Making 2005;25:387-397.
ABSTRACT  

Maximizing current treatment options: exploring psychological barriers to change
Murphy
Eur Heart J Suppl 2005;7:E10-E14.
FULL TEXT  

Costs and Effectiveness of Ximelagatran for Stroke Prophylaxis in Chronic Atrial Fibrillation
O'Brien and Gage
JAMA 2005;293:699-706.
ABSTRACT | FULL TEXT  

Hemorrhagic Complications of Anticoagulant Treatment: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Levine et al.
Chest 2004;126:287S-310S.
ABSTRACT | FULL TEXT  

Antithrombotic Therapy in Atrial Fibrillation: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Singer et al.
Chest 2004;126:429S-456S.
ABSTRACT | FULL TEXT  

Anticoagulation Therapy for Stroke Prevention in Atrial Fibrillation: How Well Do Randomized Trials Translate Into Clinical Practice?
Go et al.
JAMA 2003;290:2685-2692.
ABSTRACT | FULL TEXT  

Effect of Intensity of Oral Anticoagulation on Stroke Severity and Mortality in Atrial Fibrillation
Hylek et al.
NEJM 2003;349:1019-1026.
ABSTRACT | FULL TEXT  

A Risk Score for Predicting Stroke or Death in Individuals With New-Onset Atrial Fibrillation in the Community: The Framingham Heart Study
Wang et al.
JAMA 2003;290:1049-1056.
ABSTRACT | FULL TEXT  

A Clinical Prediction Rule to Identify Patients With Atrial Fibrillation and a Low Risk for Stroke While Taking Aspirin
van Walraven et al.
Arch Intern Med 2003;163:936-943.
ABSTRACT | FULL TEXT  

Research evidence and the individual patient
Schattner and Fletcher
QJM 2003;96:1-5.
FULL TEXT  

Oral Anticoagulants vs Aspirin in Nonvalvular Atrial Fibrillation: An Individual Patient Meta-analysis
van Walraven et al.
JAMA 2002;288:2441-2448.
ABSTRACT | FULL TEXT  

Anticoagulation Treatment in Disabled Patients
Bellelli et al.
Arch Intern Med 2002;162:107-108.
FULL TEXT